Department of Vascular and Interventional Radiology, Ghent University Hospital, C. Heymanslaan 10, 9000, Gent, Belgium.
Department of Gastroenterology and Hepatology, Ghent University Hospital, C. Heymanslaan 10, 9000, Gent, Belgium.
Eur Radiol. 2019 Feb;29(2):636-644. doi: 10.1007/s00330-018-5526-8. Epub 2018 Jul 6.
To evaluate long-term patency rates of a novel percutaneous threefold balloon dilatation protocol in benign anastomotic biliary strictures.
Patients with a benign biliary stricture after hepatobiliary surgery or liver transplantation, untreatable with endoscopy, underwent a percutaneous treatment cycle consisting of a 20-min balloon dilatation session on day one, repeated on days three and five. No catheters were left behind after the last dilatation session. Technical and clinical success as well as complications were analysed. Mean primary and secondary patency times were assessed. Cumulative primary and secondary patency rates at 6 months and 1, 2 and 3 years were determined.
Seventy patients underwent 135 dilatation treatment cycles (mean 1.9) with a technical success rate of 99%. Clinical success was achieved in 87% of the patients. Fifty-eight of 135 (43%) patients had minor and 15/135 (11%) had major complications. Mean primary and secondary patency times were 26 months and 46 months, respectively, with a median follow-up of 69 months. Cumulative primary patency rate at 6 months was 67%, at 1 year 56%, at 2 years 41% and at 3 years 36%. The cumulative secondary patency rate at 6 months was 83%, at 1 year 79%, at 2 years 70% and at 3 years 64%.
In benign anastomotic biliary strictures, a percutaneous threefold balloon dilatation treatment is effective. As long indwelling catheters are avoided, patient comfort improves.
• Percutaneous threefold balloon dilatation treatment is effective in benign anastomotic biliary strictures. • As indwelling catheters after dilatation are avoided, patient comfort improves. • The dilatation protocol can be repeated efficiently in case of recurrent stricture.
评估一种新型经皮三倍球囊扩张方案治疗良性吻合口胆管狭窄的长期通畅率。
对因肝胆手术或肝移植后出现良性胆管狭窄且内镜治疗无效的患者进行经皮治疗周期,包括第 1 天进行 20 分钟的球囊扩张,第 3 天和第 5 天重复进行。最后一次扩张后不留置导管。分析技术和临床成功率以及并发症。评估平均初次和继发性通畅时间。确定 6 个月、1、2 和 3 年时的累积初次和继发性通畅率。
70 例患者共进行了 135 次扩张治疗周期(平均 1.9 次),技术成功率为 99%。87%的患者获得临床成功。135 例患者中有 58 例(43%)发生轻微并发症,15 例(11%)发生严重并发症。平均初次和继发性通畅时间分别为 26 个月和 46 个月,中位随访时间为 69 个月。6 个月时累积初次通畅率为 67%,1 年时为 56%,2 年时为 41%,3 年时为 36%。6 个月时累积继发性通畅率为 83%,1 年时为 79%,2 年时为 70%,3 年时为 64%。
在良性吻合口胆管狭窄中,经皮三倍球囊扩张治疗是有效的。由于避免了留置导管,患者舒适度提高。
• 经皮三倍球囊扩张治疗对良性吻合口胆管狭窄有效。• 由于避免了扩张后留置导管,患者舒适度提高。• 在狭窄复发的情况下,可以有效地重复扩张方案。